TMCI TREACE MED CONCEPTS INC

Treace Medical Announces Expansion of Its Global IP Portfolio with the Grant of Two New U.S. Patents

Treace Medical Announces Expansion of Its Global IP Portfolio with the Grant of Two New U.S. Patents

PONTE VEDRA, Fla., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), is pleased to announce that the United States Patent and Trademark Office has granted to the Company U.S. Patent Nos. 11,497,528 and 11,523,845. The two new patents relate to novel methods of performing bunion surgery utilizing a bone positioning device. These patents strategically enhance Treace Medical’s comprehensive patent coverage on instrumented bunion correction techniques. The patents expand on a portfolio stemming from Treace Medical’s pioneering development work in the field, with priority dating back to 2014, and relate to Treace Medical’s Lapiplasty® 3D Bunion Correction™ system.

Treace Medical actively protects its innovations through patenting and is gratified that the United States Patent and Trademark Office and patent agencies worldwide continue to recognize the novelty of Treace Medical’s contributions to the field. The Company has a global portfolio of 50 granted patents, including 40 in the US, and 80 pending patent applications, including over 40 pending US patent applications. Additional details on Treace Medical’s patent coverage can be found at /patents.

“We are pleased that the Patent Office continues to recognize the innovative advances made by Treace Medical by granting these additional patents,” said John T. Treace, CEO, Founder and Board Member of Treace Medical. “Our intellectual property is a critical component in enabling the advancement of bunion patient care and allows Treace Medical to continue investing in solutions that benefit patients,” Mr. Treace added.

About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace Medical has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace Medical recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit .

Contacts:

Treace Medical Concepts

Mark L. Hair

Chief Financial Officer



(904) 373-5940

Investors:

Gilmartin Group

Lynn Lewis or Vivian Cervantes



EN
19/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TREACE MED CONCEPTS INC

 PRESS RELEASE

Treace Medical Concepts Reports Second Quarter 2025 Financial Results

Treace Medical Concepts Reports Second Quarter 2025 Financial Results Announces Full Market Release of Three New Bunion Technologies PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Generated revenue of $47.4 million in second quarter 2025 representing growth of 7% over the same period in...

 PRESS RELEASE

Treace Medical to Host Investor Day Highlighting New Products on Septe...

Treace Medical to Host Investor Day Highlighting New Products on September 3, 2025 PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced plans to host an investor day at 9:00 am E.T. on September 3, 2025, in New York, New York. The event will include presentations by members of management and experienced surgeon users, highlighting their experiences with the expanded technol...

 PRESS RELEASE

Treace Announces Peer-Reviewed Publication of Four-Year Results of the...

Treace Announces Peer-Reviewed Publication of Four-Year Results of the ALIGN3D™ Lapiplasty® Multicenter Prospective Clinical Study PONTE VEDRA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the peer-reviewed publication of the four-year interim results from its ALIGN3D™ multicenter prospective study demonstrating positive clinical and radiographic outcomes of the Lapiplasty® Proc...

 PRESS RELEASE

Treace to Report Second Quarter 2025 Financial Results on August 7, 20...

Treace to Report Second Quarter 2025 Financial Results on August 7, 2025 PONTE VEDRA, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship  and  Procedures, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, August 7, 2025. Company management will host a conference call to discuss financial results beginning at ...

 PRESS RELEASE

Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect...

Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology PONTE VEDRA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship  and  procedures, today announced that it filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, “Zimmer”) (NYSE: ZBH), alleging infringement of 4 patents related to Treace’s innovativ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch